摘要
目的:研究甲泼尼龙联合孟鲁斯特对复发性过敏性紫癜患儿免疫功能、细胞因子的影响。方法:选择在本院诊断为复发性过敏性紫癜的患儿作为研究对象,随机分为接受甲泼尼龙联合孟鲁斯特治疗的干预组、接受氢化可的松治疗的对照组。治疗前及治疗后4、8周时,测定外周血中Th1/Th2、Th17/Treg免疫指标以及血清中细胞因子的含量。结果:治疗后4、8周时,两组外周血中Th1、Treg细胞的含量及T-bet、FoxP3的mRNA表达量均显著高于治疗前,外周血中Th2、Th17细胞的含量及GATA-3、RORγt的mRNA表达量以及血清中NF-κB、OPN、IL-33、MK、HMGB1的含量均显著低于治疗前(P<0.05),且干预组患者外周血中Th1、Treg细胞的含量及T-bet、FoxP3的mRNA表达量均显著高于对照组,外周血中Th2、Th17细胞的含量及GATA-3、RORγt的mRNA表达量以及血清中NF-κB、OPN、IL-33、MK、HMGB1的含量均显著低于对照组(P<0.05)。结论:甲泼尼龙联合孟鲁斯特治疗复发性过敏性紫癜能够调节免疫功能、抑制细胞因子分泌。
Objective：To study the effects of methylprednisolone combined with montelukast on immune function and cytokines in children with recurrent Henoch-Schonlein purpura.Methods：Children who were diagnosed with recurrent HenochSchonlein purpura in Zigong Third People’s Hospital between September 2015 and August 2017 were selected as the research subjects and randomly divided into the intervention group who received methylprednisolone combined with montelukast therapy and the control group who received hydrocortisone therapy.The levels of Th1/Th2 and Th17/Treg immunity indexes in peripheral blood as well as cytokines in serum were measured before treatment as well as 4 and 8 weeks after treatment.Results：4 weeks and 8 weeks after treatment,Th1 and Treg cell contents as well as T-bet and FoxP3 mRNA expression in peripheral blood of both groups of patients were significantly higher than those before treatment whereas Th2 and Th17 cell contents as well as GATA-3 and RORγt mRNA expression in peripheral blood and NF-κB,OPN,IL-33,MK and HMGB1 contents in serum were significantly lower than those before treatment（P 〈0.05）,and Th1 and Treg cell contents as well as T-bet and FoxP3 mRNA expression in peripheral blood of intervention group were significantly higher than those of control group whereas Th2 and Th17 cell contents as well as GATA-3 and RORγt mRNA expression in peripheral blood and NF-κB,OPN,IL-33,MK and HMGB1 contents in serum were significantly lower than those of control group（P〈0.05）.Conclusion：methylprednisolone combined with montelukast treatment of recurrent Henoch-Schonlein purpura can regulate the immune function and inhibit the cytokine secretion.
作者
代静
DAI Jing(Department of Pediatrics,Zigong Third People’s Hospital, Zigong 643020, Sichuan, Chin)
出处
《海南医学院学报》
CAS
2018年第5期608-611,615,共5页
Journal of Hainan Medical University
基金
自贡市科技局课题项目(J2015029)~~
关键词
过敏性紫癜
甲泼尼龙
孟鲁斯特
免疫功能
细胞因子
Henoch-Schonlein purpura
methylprednisolone
montelukast
immune function
cytokine
